IDEAYA BIOSCIENCES INC

NASDAQ: IDYA (IDEAYA Biosciences, Inc.)

最近更新时间: 4天之前, 7:08AM

33.69

-0.62 (-1.81%)

前收盘价格 34.31
收盘价格 34.62
成交量 546,937
平均成交量 (3个月) 1,194,552
市值 2,953,481,216
预期市盈率 (P/E Forward) 4.65
价格/销量 (P/S) 14.72
股市价格/股市净资产 (P/B) 2.88
52周波幅
13.45 (-60%) — 36.55 (8%)
利润日期 4 Nov 2025
营业利益率 (TTM) -5,147.81%
稀释每股收益 (EPS TTM) -3.65
季度收入增长率 (YOY) 78.50%
总债务/股东权益 (D/E MRQ) 2.54%
流动比率 (MRQ) 13.92
营业现金流 (OCF TTM) -264.11 M
杠杆自由现金流 (LFCF TTM) -164.58 M
资产报酬率 (ROA TTM) -21.84%
股东权益报酬率 (ROE TTM) -31.34%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 IDEAYA Biosciences, Inc. 看涨 看涨

AIStockmoo 评分

1.5
分析师共识 1.5
内部交易活动 NA
价格波动 -3.0
技术平均移动指标 3.5
技术振荡指标 4.0
平均 1.50

相关股票

股票 市值 DY P/E(TTM) P/B
IDYA 3 B - - 2.88
IONS 13 B - - 21.49
RNA 11 B - - 5.73
NUVL 8 B - - 10.04
RYTM 7 B - - 48.92
PTCT 6 B - 9.05 -

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 0.90%
机构持股比例 117.09%
52周波幅
13.45 (-60%) — 36.55 (8%)
目标价格波幅
30.00 (-10%) — 79.00 (134%)
79.00 (JP Morgan, 134.49%) 购买
46.00 (36.54%)
30.00 (Goldman Sachs, -10.95%) 保留
平均值 50.78 (50.73%)
总计 8 购买, 1 保留
平均价格@调整类型 28.56
公司 日期 目标价格 调整类型 价格@调整类型
Truist Securities 24 Nov 2025 59.00 (75.13%) 购买 34.67
Mizuho 11 Nov 2025 46.00 (36.54%) 购买 32.01
12 Sep 2025 44.00 (30.60%) 购买 24.61
JP Morgan 23 Oct 2025 79.00 (134.49%) 购买 28.42
BTIG 21 Oct 2025 62.00 (84.03%) 购买 29.20
Goldman Sachs 21 Oct 2025 30.00 (-10.95%) 保留 29.20
RBC Capital 21 Oct 2025 41.00 (21.70%) 购买 29.20
09 Sep 2025 38.00 (12.79%) 购买 24.74
Guggenheim 18 Sep 2025 50.00 (48.41%) 购买 26.22
Stephens & Co. 09 Sep 2025 45.00 (33.57%) 购买 24.74
JMP Securities 08 Sep 2025 45.00 (33.57%) 购买 23.39
显示更多

该时间范围内无数据。

日期 类型 细节
04 Dec 2025 公告 IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
01 Dec 2025 公告 IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
28 Nov 2025 公告 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
24 Nov 2025 公告 IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
04 Nov 2025 公告 IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
31 Oct 2025 公告 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
27 Oct 2025 公告 IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
20 Oct 2025 公告 IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025
20 Oct 2025 公告 IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress
26 Sep 2025 公告 IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08 Sep 2025 公告 IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
08 Sep 2025 公告 IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
07 Sep 2025 公告 IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票